Rare Diseases and their Unique Challenges

Authors

  • Advait Wattal Moorestown High School
  • Lucas Martz University of Pennsylvania

DOI:

https://doi.org/10.47611/jsrhs.v13i4.8088

Keywords:

rare disease, health-policy, orphan drugs, Hemophilia

Abstract

By definition, rare diseases affect a very small percentage of the population; however, that fraction still represents a significant 300 million people worldwide. The scarcity of affected patients and knowledgeable clinicians for each rare disease presents multiple unique challenges for all individuals and institutions involved. Clinicians struggle because the rarity of these diseases prohibits easy access to information about symptoms, which leads to delays in accurate diagnosis. Patients struggle with the uncertainty of living with undiagnosed conditions, which can lead to lowered quality of life and an economic burden, as well as anxiety issues and depression. Additionally, researchers and pharmaceutical companies have difficulty finding adequate patients for clinical trials, while dealing with uncertain commercial viability of any treatment. This coupled with the myriad of rare diseases means there is not enough funding for each disease to make significant progress in short amounts of time. The lack of recognition from governments and international organizations until recently slowed any progress made towards rare disease treatment. Solutions to these challenges will require a multi-pronged approach consisting of digital platforms such as patient networks, increased training among physicians, new treatment strategies like precision medicine, government intervention, as well as incentives for companies to invest in rare disease treatment. The key to eventually solving each challenge is awareness of the public and medical community alike.

Downloads

Download data is not yet available.

References or Bibliography

Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M, Summar M, Wattanasirichaigoon D. Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges. International Journal of Environmental Research and Public Health. 2023; 20(6):4732. https://doi.org/10.3390/ijerph20064732

Amalanathan, S. (2023). Importance Of Rare Diseases AwarenessFor Medical And Nursing Students At KSA. Journal of Survey in Fisheries Sciences, 2325-2341.https://doi.org/10.53555/sfs.v10i1.898

Al Mukaddam, M., Toder, K. S., Davis, M., Cali, A., Liljesthröm, M., Hollywood, S., … Kaplan, F. S. (2022). The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey. Expert Review of Pharmacoeconomics & Outcomes Research, 22(8), 1199–1213. https://doi.org/10.1080/14737167.2022.2115360

Centers for Disease Control and Prevention. (2024, May 15). Data and statistics on hemophilia. Centers for Disease Control and Prevention. https://www.cdc.gov/hemophilia/data-research/index.html

Chung, C. C. Y., Hong Kong Genome Project, Chu, A. T. W., & Chung, B. H. Y. (2022). Rare disease emerging as a global public health priority. Frontiers in Public Health, 10, 1028545. https://doi.org/10.3389/fpubh.2022.1028545

Dance, A. Rare-disease studies seek online giving. Nature (2011). https://doi.org/10.1038/news.2011.387

Delaye, J., Cacciatore, P., & Kole, A. (2022). Valuing the “burden” and impact of rare diseases: a scoping review. Frontiers in Pharmacology, 13, 914338. https://doi.org/10.3389/fphar.2022.914338

Fermaglich, L. J., & Miller, K. L. (2023). A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet Journal of Rare Diseases, 18(1), 163. https://doi.org/10.1186%2Fs13023-023-02790-7

Ferreira, C. R. (2019). The burden of rare diseases. American journal of medical genetics Part A, 179(6), 885-892.

https://doi.org/10.1002/ajmg.a.61124

Gainotti S, Mascalzoni D, Bros-Facer V, Petrini C, Floridia G, Roos M, Salvatore M, Taruscio D. Meeting Patients’ Right to the Correct Diagnosis: Ongoing International Initiatives on Undiagnosed Rare Diseases and Ethical and Social Issues. International Journal of Environmental Research and Public Health. 2018; 15(10):2072. https://doi.org/10.3390/ijerph15102072

Garrino, L., Picco, E., Finiguerra, I., Rossi, D., Simone, P., & Roccatello, D. (2015). Living with and treating rare diseases: experiences of patients and professional health care providers. Qualitative Health Research, 25(5), 636-651. https://doi.org/10.1177/1049732315570116

Gimenez-Lozano, C., Páramo-Rodríguez, L., Cavero-Carbonell, C., Corpas-Burgos, F., López-Maside, A., Guardiola-Vilarroig, S., & Zurriaga, O. (2022). Rare diseases: needs and impact for patients and families: a cross-sectional study in the Valencian Region, Spain. International Journal of Environmental Research and Public Health, 19(16), 10366. https://doi.org/10.3390%2Fijerph191610366

Graf von der Schulenburg, JM., Frank, M. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. Eur J Health Econ 16, 113–118 (2015). https://doi.org/10.1007/s10198-014-0639-8

Halley, M.C., Smith, H.S., Ashley, E.A. et al. A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States. Nat Genet 54, 219–222 (2022). https://doi.org/10.1038/s41588-022-01027-w

Health, T. L. G. (2024). The landscape for rare diseases in 2024. The Lancet. Global health, 12(3), e341. https://doi.org/10.1016/S2214-109X(24)00056-1

Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen, Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, Volume 47, 2016, Pages 20-33, ISSN 0167-6296, https://doi.org/10.1016/j.jhealeco.2016.01.012.

Kremer, M. (2004). Strong medicine. Google Books. https://books.google.com/books?hl=en&lr=&id=2wp12_qCg7YC&oi=fnd&pg=PR9&dq=hesitancy%2Bfor%2Bbig%2Bcompanies%2Bto%2Binvest%2Bin%2Bcures%2Bfor%2Brare%2Bdiseases%2C%2Bwhich%2Bslows%2Bdown%2Bresearch%2Bas%2Ba%2Bwhole&ots=W_7ZDqroSe&sig=U4DSMavBZogFd0DzAL8QRFEj_hg#v=onepage&q=reluctant&f=false

Mikulic, M. (2024, May 16). Rare diseases funding by US National Institutes for Health 2013-2025. Statista. https://www.statista.com/statistics/713320/rare-diseases-funding-by-the-national-institutes-for-health/#:~:text=Rare%20diseases%20funding%20by%20the%20NIH%20was%20around%206.9%20billion,FY%202024%20and%20FY%202025

NORD. (2020). Barriers to rare disease diagnosis, care and treatment in …

https://rarediseases.org/wp-content/uploads/2020/11/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf

NSAA. (2017). The challenges of parenting a child with a rare disease. Noonan Syndrome Awareness Association. https://noonansyndrome.com.au/the-challenges-of-parenting-a-child-with-a-rare-disease/

Pingali, V., & Das, N. (2021). Rare diseases require support too. Vikalpa, 46(2), 129-134. https://doi.org/10.1177/02560909211024554

Rare diseases, common challenges. Nat Genet 54, 215 (2022). https://doi.org/10.1038/s41588-022-01037-8

Roberts AD, Wadhwa R. Orphan Drug Approval Laws. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572052/

Schieppati, A., Henter, J. I., Daina, E., & Aperia, A. (2008). Why rare diseases are an important medical and social issue. The Lancet, 371(9629), 2039-2041. https://doi.org/10.1016/s0140-6736(08)60872-7

Shimkus, J. (2002, June 11). Rare diseases act of 2002. congress.gov. https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf

Stoller, J. K. (2018). The challenge of rare diseases. Chest, 153(6), 1309-1314. https://doi.org/10.1016/j.chest.2017.12.018

Strandburg, K. J., Frischmann, B. M., & Cui, C. (2014). The rare diseases clinical research network and the urea cycle disorders consortium as nested knowledge commons. Knowledge Commons Governance (B. Frischmann, M. Madison, and K. Strandburg, eds.)(OUP 2014), NYU Law and Economics Research Paper, (14-43).

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2538609

Talha, M., Ali, M.H. Palovarotene approved as first treatment for fibrodysplasia ossificans progressiva (FOP). J Rare Dis 3, 8 (2024). https://doi.org/10.1007/s44162-024-00032-3

Taruscio, D., Gahl, W.A. Rare diseases: challenges and opportunities for research and public health. Nat Rev Dis Primers 10, 13 (2024). https://doi.org/10.1038/s41572-024-00505-1

Uhlenbusch, N., Löwe, B., Härter, M., Schramm, C., Weiler-Normann, C., & Depping, M. K. (2019). Depression and anxiety in patients with different rare chronic diseases: A cross-sectional study. PloS one, 14(2), e0211343.

https://doi.org/10.1371/journal.pone.0211343

Villalón-García I, Álvarez-Córdoba M, Suárez-Rivero JM, Povea-Cabello S, Talaverón-Rey M, Suárez-Carrillo A, Munuera-Cabeza M, Sánchez-Alcázar JA. Precision Medicine in Rare Diseases. Diseases. 2020; 8(4):42. https://doi.org/10.3390/diseases8040042

Published

11-30-2024

How to Cite

Wattal, A., & Martz, L. (2024). Rare Diseases and their Unique Challenges. Journal of Student Research, 13(4). https://doi.org/10.47611/jsrhs.v13i4.8088

Issue

Section

HS Review Articles